220846-33-3Relevant academic research and scientific papers
PHARMACEUTICAL COMPOSITION AND PROCESS
-
Page/Page column 7-8, (2008/06/13)
There is provided a formulation comprising N-(2-chloro-6-methylbenzoyl)-4- [(2,6-dichlorobenzoyl)amino]-L-phenylalanine-2(diethylamino)ethyl ester and poloxamer 188 which is manufactured by a hot melt process.
N-Aroyl-L-phenylalanine derivatives as VCAM/VLA-4 antagonists.
Sidduri, Achyutharao,Tilley, Jefferson W,Lou, Jian Ping,Chen,Kaplan, Gerry,Mennona, Frank,Campbell, Robert,Guthrie, Robert,Huang, Tai-Nan,Rowan, Karen,Schwinge, Virginia,Renzetti, Louis M
, p. 2479 - 2482 (2007/10/03)
A series of N-benzoyl-4-[(2,6-dichlorobenzoyl)amino]-L-phenylalanine derivatives was prepared in order to optimize the substitution on the N-benzoyl moiety for VCAM/VLA-4 antagonist activity. Disubstitution in the 2- and 6-positions is favored and a range
N-aroylphenylalanine derivative VCAM-1 inhibitors
-
, (2008/06/13)
Compounds of the formula: are disclosed which have activity as inhibitors of binding between VCAM-1 and cells expressing VLA-4. Such compounds are useful for treating diseases whose symptoms and/or damage are related to the binding of VCAM-1 to cells expr
